date:Aug 17, 2012
Responding to EFSAs April, 2012, rejection of its article 13.5 submission under the EU nutrition and health claims regulation (NHCR), Merck said bioavailability and efficacy data should be reconsidered, as EFSAs health claims panel had misinterpreted it the first time around.
But EFSAs Dietetic Products, Nutrition and Allergies (NDA) dismissed the Merck appeal as ungrounded and reiterated its earlier opinionthat a cause and effect relationship has not been established between the consumption of